Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||94%|
|1 Day Vol Adjusted Return||0.6|
|1 Month Vol Adjusted Return||3.0|
|3 Month Vol Adjusted Return||0.2|
|6 Month Vol Adjusted Return||-3.8|
|20 Days SMA Price ZScore||1.1|
|50 Days SMA Price ZScore||1.2|
|12 -26 Days PPO||1.5|
|1 Month Average Short Volume Ratio||53.4|
|1 Day Volume Change ZScore||-0.5|
|1 Month Daily Vol||1.4|
Insiders who purchased US$933k worth of Laboratory Corporation of America Holdings ( NYSE:LH ) shares over the past...
Redi.Health Inc.'s app is now offered to patients through the Patient Access Solutions division of Labcorp, a global diagnostic and drug development company.
Ladies and gentlemen, thank you for standing by, and welcome to the Labcorp Second quarter 2022 Earnings Call. With me today are Adam Schechter, chairman and chief executive officer; and Glenn Eisenberg, executive vice president and chief financial officer. This morning, in the investor relations section of our website at www.labcorp.com, we posted both a press release and an investor relations presentation with additional information on our business and operations, which includes a reconcilia...
As Covid-19 testing slowed in recent months, Burlington-based Labcorp reported a small decrease in revenue for the second quarter of 2022 down to $3.7 billion and announced plans to spin-off its clinical development business.
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Labcorp will spin-off its wholly owned clinical development business, with the expectation that it will become an independent, publicly traded company. Labcorp will remain in Burlington and focus on its laboratory services.
LabCorp (LH) delivered earnings and revenue surprises of 6.21% and 3.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Shares of Labcorp gained 4.2% in premarket trading on Thursday after beating earnings expectations for the second quarter and announcing plans to spin off its clinical-development business, which provides contract-research organization services, next year. The company reported earnings of $358.6 million, or $3.87 per share, in the second quarter of 2022, compared with $467.4 million, or $4.76 per share, in the same three months of last year. Adjusted earnings per share were $4.96, against a Fact
Laboratory Corp of America Holdings (NYSE: LH) plans to spin off its unit focused on the clinical development business. Wall Street Journal was the first to report the news. The clinical drug trial business operates as a Contract Research Organization, providing Phase I-IV clinical trial management, market access, and technology solutions to pharmaceutical and biotechnology organizations. According to WSJ, the move will create a new stand-alone company in the fast-growing contract-research secto